vs
Side-by-side financial comparison of Baldwin Insurance Group, Inc. (BWIN) and IDEAYA Biosciences, Inc. (IDYA). Click either name above to swap in a different company.
Baldwin Insurance Group, Inc. is the larger business by last-quarter revenue ($347.3M vs $207.8M, roughly 1.7× IDEAYA Biosciences, Inc.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs -7.5%, a 64.9% gap on every dollar of revenue. IDEAYA Biosciences, Inc. produced more free cash flow last quarter ($142.2M vs $-68.9M).
The Baldwin Piano Company is an American piano brand. It was once the largest US-based manufacturer of keyboard instruments and was known by the slogan, "America's Favorite Piano". Since 2001, it has been a subsidiary of Gibson Brands, Inc. Baldwin ceased domestic production in December 2008, moving its piano manufacturing to China.
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
BWIN vs IDYA — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $347.3M | $207.8M |
| Net Profit | $-25.9M | $119.2M |
| Gross Margin | — | — |
| Operating Margin | -3.8% | 52.2% |
| Net Margin | -7.5% | 57.4% |
| Revenue YoY | 5.3% | — |
| Net Profit YoY | -28.3% | 330.1% |
| EPS (diluted) | $-0.38 | $1.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $347.3M | — | ||
| Q3 25 | $365.4M | $207.8M | ||
| Q2 25 | $378.8M | — | ||
| Q1 25 | $413.4M | — | ||
| Q4 24 | $329.9M | — | ||
| Q3 24 | $338.9M | $0 | ||
| Q2 24 | $339.8M | $0 | ||
| Q1 24 | $380.4M | $0 |
| Q4 25 | $-25.9M | — | ||
| Q3 25 | $-18.7M | $119.2M | ||
| Q2 25 | $-3.2M | — | ||
| Q1 25 | $13.9M | — | ||
| Q4 24 | $-20.2M | — | ||
| Q3 24 | $-8.4M | $-51.8M | ||
| Q2 24 | $-17.6M | $-52.8M | ||
| Q1 24 | $21.6M | $-39.6M |
| Q4 25 | -3.8% | — | ||
| Q3 25 | 0.9% | 52.2% | ||
| Q2 25 | 7.4% | — | ||
| Q1 25 | 13.6% | — | ||
| Q4 24 | -1.7% | — | ||
| Q3 24 | 4.5% | — | ||
| Q2 24 | 4.8% | — | ||
| Q1 24 | 9.0% | — |
| Q4 25 | -7.5% | — | ||
| Q3 25 | -5.1% | 57.4% | ||
| Q2 25 | -0.8% | — | ||
| Q1 25 | 3.4% | — | ||
| Q4 24 | -6.2% | — | ||
| Q3 24 | -2.5% | — | ||
| Q2 24 | -5.2% | — | ||
| Q1 24 | 5.7% | — |
| Q4 25 | $-0.38 | — | ||
| Q3 25 | $-0.27 | $1.33 | ||
| Q2 25 | $-0.05 | — | ||
| Q1 25 | $0.20 | — | ||
| Q4 24 | $-0.31 | — | ||
| Q3 24 | $-0.13 | $-0.60 | ||
| Q2 24 | $-0.28 | $-0.68 | ||
| Q1 24 | $0.33 | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $123.7M | $786.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $600.2M | $1.1B |
| Total Assets | $3.9B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $123.7M | — | ||
| Q3 25 | $89.7M | $786.9M | ||
| Q2 25 | $105.7M | — | ||
| Q1 25 | $81.8M | — | ||
| Q4 24 | $90.0M | — | ||
| Q3 24 | $181.8M | $920.0M | ||
| Q2 24 | $208.3M | $701.7M | ||
| Q1 24 | $112.1M | $698.8M |
| Q4 25 | $600.2M | — | ||
| Q3 25 | $619.7M | $1.1B | ||
| Q2 25 | $630.8M | — | ||
| Q1 25 | $619.6M | — | ||
| Q4 24 | $583.2M | — | ||
| Q3 24 | $595.4M | $1.2B | ||
| Q2 24 | $590.9M | $931.7M | ||
| Q1 24 | $597.9M | $935.3M |
| Q4 25 | $3.9B | — | ||
| Q3 25 | $3.8B | $1.2B | ||
| Q2 25 | $3.7B | — | ||
| Q1 25 | $3.5B | — | ||
| Q4 24 | $3.5B | — | ||
| Q3 24 | $3.5B | $1.2B | ||
| Q2 24 | $3.7B | $973.7M | ||
| Q1 24 | $3.5B | $961.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-29.4M | $142.2M |
| Free Cash FlowOCF − Capex | $-68.9M | $142.2M |
| FCF MarginFCF / Revenue | -19.9% | 68.4% |
| Capex IntensityCapex / Revenue | 11.4% | 0.0% |
| Cash ConversionOCF / Net Profit | — | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | $-137.8M | $13.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-29.4M | — | ||
| Q3 25 | $41.0M | $142.2M | ||
| Q2 25 | $-16.7M | — | ||
| Q1 25 | $-64.0M | — | ||
| Q4 24 | $51.5M | — | ||
| Q3 24 | $32.4M | $-49.2M | ||
| Q2 24 | $18.3M | $-32.9M | ||
| Q1 24 | $3.0M | $-43.8M |
| Q4 25 | $-68.9M | — | ||
| Q3 25 | $32.2M | $142.2M | ||
| Q2 25 | $-28.1M | — | ||
| Q1 25 | $-72.9M | — | ||
| Q4 24 | $10.4M | — | ||
| Q3 24 | $22.2M | $-49.7M | ||
| Q2 24 | $7.8M | $-33.9M | ||
| Q1 24 | $-5.1M | $-45.1M |
| Q4 25 | -19.9% | — | ||
| Q3 25 | 8.8% | 68.4% | ||
| Q2 25 | -7.4% | — | ||
| Q1 25 | -17.6% | — | ||
| Q4 24 | 3.2% | — | ||
| Q3 24 | 6.6% | — | ||
| Q2 24 | 2.3% | — | ||
| Q1 24 | -1.4% | — |
| Q4 25 | 11.4% | — | ||
| Q3 25 | 2.4% | 0.0% | ||
| Q2 25 | 3.0% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 12.4% | — | ||
| Q3 24 | 3.0% | — | ||
| Q2 24 | 3.1% | — | ||
| Q1 24 | 2.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.19× | ||
| Q2 25 | — | — | ||
| Q1 25 | -4.59× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.14× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BWIN
| Insurance Advisory Solutions | $157.9M | 45% |
| Underwriting Capacity Technology Solutions | $129.5M | 37% |
| Consultingand Service Fee Revenue | $20.9M | 6% |
| Policy Feeand Installment Fee Revenue | $20.4M | 6% |
| Other | $7.3M | 2% |
| Earned Premium | $6.9M | 2% |
| Other Insurance Product Line | $4.4M | 1% |
IDYA
Segment breakdown not available.
